Citadel Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-180,772
| Closed | -$2.25M | – | 8515 |
|
|
2016
Q4 | $2.25M | Buy |
180,772
+135,539
| +300% | +$1.63M | ﹤0.01% | 2815 |
|
|
2016
Q3 | $619K | Sell |
45,233
-33,478
| -43% | -$336K | ﹤0.01% | 4526 |
|
|
2016
Q2 | $582K | Sell |
78,711
-33,349
| -30% | -$250K | ﹤0.01% | 4285 |
|
|
2016
Q1 | $716K | Buy |
112,060
+101,335
| +945% | +$568K | ﹤0.01% | 3904 |
|
|
2015
Q4 | $67K | Sell |
10,725
-36,544
| -77% | -$240K | ﹤0.01% | 7074 |
|
|
2015
Q3 | $276K | Sell |
47,269
-119,957
| -72% | -$924K | ﹤0.01% | 5692 |
|
|
2015
Q2 | $1.38M | Sell |
167,226
-71,332
| -30% | -$631K | ﹤0.01% | 3535 |
|
|
2015
Q1 | $1.97M | Buy |
238,558
+181,761
| +320% | +$1.34M | ﹤0.01% | 3087 |
|
|
2014
Q4 | $390K | Sell |
56,797
-259,809
| -82% | -$1.62M | ﹤0.01% | 5070 |
|
|
2014
Q3 | $1.71M | Buy |
316,606
+69,671
| +28% | +$407K | ﹤0.01% | 3033 |
|
|
2014
Q2 | $1.57M | Sell |
246,935
-469,018
| -66% | -$3.23M | ﹤0.01% | 2977 |
|
|
2014
Q1 | $5.77M | Buy |
715,953
+331,782
| +86% | +$2.58M | 0.01% | 1650 |
|
|
2013
Q4 | $2.62M | Buy |
384,171
+158,426
| +70% | +$855K | ﹤0.01% | 2267 |
|
|
2013
Q3 | $4.15M | Sell |
225,745
-95,268
| -30% | -$1.85M | 0.01% | 1727 |
|
|
2013
Q2 | $5.61M | Buy |
+321,013
| New | +$5.69M | 0.01% | 1466 |
|
Other funds holding ARIA
Citadel Advisors's ARIA Position: Q1 2017 in Review
Citadel Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 180,772 shares — an estimated $2.25M sold.
Citadel Advisors first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $5.77M in Q1 2014. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Citadel Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Citadel Advisors sold 180,772 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $2.25M.
- Citadel Advisors first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Citadel Advisors's Ariad Pharmaceuticals Inc position peaked at $5.77M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.